Log in to your Inderes Free account to see all free content on this page.
Orexo
17.54 SEK -15.67%Be the first to follow this company
Orexo is a Swedish pharmaceutical company that develops medicines based on proprietary formulation technologies that meet major medical needs. In the US market, Orexo offers treatment solutions for patients suffering from opioid addiction and related diseases. Products targeting other therapeutic areas are developed and commercialized worldwide in collaboration with partners. The head office, where the research and development work is conducted, is located in Uppsala.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
ORX
Daily low / high price
16.82 / 18.18
SEK
Market cap
608.82M SEK
Turnover
2.69M SEK
Volume
154K
Latest videos
Financial calendar
Interim report
17.07.2024
Interim report
14.11.2024
Annual report
06.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Novo A/S | 27.8 % | 27.8 % |
Avanza Pension | 6.6 % | 6.6 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Orexo Q2 2024 Interim Report
Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio